An economical process technology has been developed using indigenously available key starting materials. CSIR-CDRI has received the permission from Central Drugs Standard Control Organization for conducting the Phase III clinical trial with Umifenovir entitled "Randomised, double blind, placebo controlled trial of efficacy, safety and tolerability of Antiviral drug Umifenovir vs standard care of therapy in non-severe COVID-19 patients.”
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.
Central Research Institute (CRI)
Acces sibility Controls